Mycophenolate mofetil and bronchiectasis in kidney transplant patients: A possible relationship

Transplantation

Volumn 81, Issue 2, 2006, Pages 287-289

  Rook, Mieneke ^a   Postma, Dirkje S ^a   Van Der Jagt, Eric J ^a   Van Minnen, Cees A ^a   Homan Van Der Heide, Jaap J ^a   Ploeg, Rutger J ^a   Van Son, Willem J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bronchiectasis; Immunosuppression; Mycophenolate mofetil; Pulmonary complaints; Renal transplantation

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADULT; ARTICLE; ATELECTASIS; BRONCHIECTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE DURATION; DRUG FEVER; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENTERIC FEEDING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ATROPHY; MALE; PNEUMONIA; PRIORITY JOURNAL; SPUTUM; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; CASE REPORT; MIDDLE AGED; RADIOGRAPHY; TIME;

ADULT; BRONCHIECTASIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644856880     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000188638.28003.96     Document Type: Article

References (13)

1. Barker AP. Bronchiectasis. N Engl J Med 2002; 346: 1383-1393.
2. Rosen FS, Cooper MD, Wedgwood RJP. The primary immunodeficiencies. N Engl J Med 1995; 333: 431-440.
3. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
4. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47: 215-245.
5. Hill SL, Mitchell JL, Burnett D, Stockley RA. IgG subclasses in the serum and sputum from patients with bronchiectasis. Thorax 1998; 53: 463-468.
6. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991; 325: 110-117.
7. Smak Gregoor PJH, van Gelder T, van Riemsdijk-van Overbeeke IC, et al. Unusual presentation of herpes virus infections in renal transplant recipients exposed to high mycophenolic acid plasma concentrations. Transpl Infect Dis 2003; 5: 79-83.
8. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266.
9. Cransberg K, Cornelissen MEA, Davin JC, et al. Improved outcome of pediatric kidney transplantations in the Netherlands - effect of the introduction of mycophenolate mofetil? Pediatr Transplant 2005; 9: 104-111.
10. Raab M, Daxecker H, Karimi A, et al. In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clin Chim Acta 2001; 310: 89-98.
11. Valentin JF, Bruijn JA, Paul LC. Donor treatment with mycophenolate mofetil: protection against ischemia-reperfusion injury in the rat. Transplantation 2000; 69: 344-350.
12. Papadimitriou JC, Drachenberg CB, Beskow CO, et al. Graft-versus-host disease-like features in mycophenolate mofetil-related colitis. Transplant Proc 2001; 33: 2237-2238.
13. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation 1998; 66: 1115-1116.